Matches in SemOpenAlex for { <https://semopenalex.org/work/W2315661674> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W2315661674 endingPage "720" @default.
- W2315661674 startingPage "710" @default.
- W2315661674 abstract "Clinical trials in chronic lymphocytic leukemia (CLL) have focused mainly on younger fit patients until recently. However, CLL is a disease of elderly and many patients have significant comorbid conditions which together with advanced age preclude the use of aggressive regimens like FCR (fludarabine, cyclophosphamide, rituximab). Therefore, parameters such as performance status, renal function and number/severity of comorbidities together with clinical judgment should be used to guide the decision-making process regarding intensity of treatment. Two large randomized trials recently demonstrated that addition of monoclonal anti-CD20 antibodies (obinutuzumab, rituximab, and ofatumumab) to chlorambucil in untreated comorbid patients lead to improvement in complete remission rate, progression-free survival and even overall survival (obinutuzumab-chlorambucil and rituximab-chlorambucil), with acceptable toxicity profile. Thus, chemoimmunotherapy combining chlorambucil with an anti-CD20 antibody is the new standard approach for elderly/comorbid CLL patients in the first line. Treatment of relapsed/refractory disease in this patient population is very challenging and data regarding this subpopulation are rather limited. Impressive efficacy of novel targeted small molecules interfering with B-cell receptor signaling, namely Bruton tyrosine kinase inhibitor ibrutinib and phosphatidylinositol-3 kinase delta inhibitor idelalisib, radically changed the treatment paradigms for relapsed/refractory CLL; relatively mild toxicity of these agents make them very good candidates for elderly/comorbid patients. Other options for relapsed/refractory disease include alemtuzumab, ofatumumab, high-dose glucocorticoids+rituximab and bendamustine+rituximab. This review summarizes the current knowledge on prognostication and therapy of elderly and comorbid patients with CLL. Keywords: Chronic lymphocytic leukemia, comorbidity, health-related quality of life, ibrutinib, idelalisib, obinutuzumab, ofatumumab, comprehensive geriatric assessment." @default.
- W2315661674 created "2016-06-24" @default.
- W2315661674 creator A5069046684 @default.
- W2315661674 date "2016-09-02" @default.
- W2315661674 modified "2023-09-24" @default.
- W2315661674 title "Therapeutic Approach to Patients with Chronic Lymphocytic Leukemia and Significant Comorbid Conditions" @default.
- W2315661674 doi "https://doi.org/10.2174/1568009616666160408145850" @default.
- W2315661674 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27055578" @default.
- W2315661674 hasPublicationYear "2016" @default.
- W2315661674 type Work @default.
- W2315661674 sameAs 2315661674 @default.
- W2315661674 citedByCount "6" @default.
- W2315661674 countsByYear W23156616742017 @default.
- W2315661674 countsByYear W23156616742018 @default.
- W2315661674 countsByYear W23156616742019 @default.
- W2315661674 countsByYear W23156616742020 @default.
- W2315661674 crossrefType "journal-article" @default.
- W2315661674 hasAuthorship W2315661674A5069046684 @default.
- W2315661674 hasConcept C126322002 @default.
- W2315661674 hasConcept C143998085 @default.
- W2315661674 hasConcept C203014093 @default.
- W2315661674 hasConcept C2776694085 @default.
- W2315661674 hasConcept C2776755627 @default.
- W2315661674 hasConcept C2777607594 @default.
- W2315661674 hasConcept C2777866208 @default.
- W2315661674 hasConcept C2777938653 @default.
- W2315661674 hasConcept C2778461978 @default.
- W2315661674 hasConcept C2778714382 @default.
- W2315661674 hasConcept C2779015954 @default.
- W2315661674 hasConcept C2779260929 @default.
- W2315661674 hasConcept C2779263901 @default.
- W2315661674 hasConcept C2779338263 @default.
- W2315661674 hasConcept C2779675984 @default.
- W2315661674 hasConcept C2779878957 @default.
- W2315661674 hasConcept C2780653079 @default.
- W2315661674 hasConcept C2780790343 @default.
- W2315661674 hasConcept C2781442060 @default.
- W2315661674 hasConcept C2908647359 @default.
- W2315661674 hasConcept C2911091166 @default.
- W2315661674 hasConcept C71924100 @default.
- W2315661674 hasConcept C99454951 @default.
- W2315661674 hasConceptScore W2315661674C126322002 @default.
- W2315661674 hasConceptScore W2315661674C143998085 @default.
- W2315661674 hasConceptScore W2315661674C203014093 @default.
- W2315661674 hasConceptScore W2315661674C2776694085 @default.
- W2315661674 hasConceptScore W2315661674C2776755627 @default.
- W2315661674 hasConceptScore W2315661674C2777607594 @default.
- W2315661674 hasConceptScore W2315661674C2777866208 @default.
- W2315661674 hasConceptScore W2315661674C2777938653 @default.
- W2315661674 hasConceptScore W2315661674C2778461978 @default.
- W2315661674 hasConceptScore W2315661674C2778714382 @default.
- W2315661674 hasConceptScore W2315661674C2779015954 @default.
- W2315661674 hasConceptScore W2315661674C2779260929 @default.
- W2315661674 hasConceptScore W2315661674C2779263901 @default.
- W2315661674 hasConceptScore W2315661674C2779338263 @default.
- W2315661674 hasConceptScore W2315661674C2779675984 @default.
- W2315661674 hasConceptScore W2315661674C2779878957 @default.
- W2315661674 hasConceptScore W2315661674C2780653079 @default.
- W2315661674 hasConceptScore W2315661674C2780790343 @default.
- W2315661674 hasConceptScore W2315661674C2781442060 @default.
- W2315661674 hasConceptScore W2315661674C2908647359 @default.
- W2315661674 hasConceptScore W2315661674C2911091166 @default.
- W2315661674 hasConceptScore W2315661674C71924100 @default.
- W2315661674 hasConceptScore W2315661674C99454951 @default.
- W2315661674 hasIssue "8" @default.
- W2315661674 hasLocation W23156616741 @default.
- W2315661674 hasLocation W23156616742 @default.
- W2315661674 hasOpenAccess W2315661674 @default.
- W2315661674 hasPrimaryLocation W23156616741 @default.
- W2315661674 hasRelatedWork W1550739321 @default.
- W2315661674 hasRelatedWork W2014078906 @default.
- W2315661674 hasRelatedWork W2034398106 @default.
- W2315661674 hasRelatedWork W2113254351 @default.
- W2315661674 hasRelatedWork W2161184804 @default.
- W2315661674 hasRelatedWork W2294347960 @default.
- W2315661674 hasRelatedWork W2315661674 @default.
- W2315661674 hasRelatedWork W2606155555 @default.
- W2315661674 hasRelatedWork W2620696047 @default.
- W2315661674 hasRelatedWork W4323810490 @default.
- W2315661674 hasVolume "16" @default.
- W2315661674 isParatext "false" @default.
- W2315661674 isRetracted "false" @default.
- W2315661674 magId "2315661674" @default.
- W2315661674 workType "article" @default.